Pervasive gaps in Amazonian ecological research

Biodiversity loss is one of the main challenges of our time, and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space. While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes, vast areas of the tropics remain understudied. In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity, but it remains among the least known forests in America and is often underrepresented in biodiversity databases. To worsen this situation, human-induced modifications may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge, it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost

Effect Of Praziquantel In Liposomes On Schistosoma Mansoni Eggs At Different Development Stages [efeito Do Praziquantel Incorporado A Lipossomas Nos Diferentes Estágios De Desenvolvimento Dos Ovos De Schistosoma Mansoni]

Mansonian schistosomiasis is caused by an intravascular digenetic trematode Schistosoma mansoni. Praziquantel (PZQ) and oxamniquine (OXA) are the drugs of choice for the treatment of this disease. However, both drugs are subject to some limitations in their action and cases of tolerance and resistance have been reported. Moreover, tolerance and resistance cases have been reported. For this reason, there is an urgent need for research on new alternatives aimed at improving the action of existing drugs, such as the incorporation of these drugs into liposomes. In this study, the efficiency of action of liposome- encapsulated praziquantel (lip.PZQ) on oviposition by S. mansoni, strain BH, was assessed in Mus musculus mices (SPF Swiss mice). Four PZQ and lip.PZQ doses (47; 60; 250 e 300mg/kg) were tested. Some mice were treated 30 days post-infection and others after 45 days. The oogram analyses showed that the most effective lip.PZQ treatment was 300mg/kg dose given on the 45th day post infection, which reduced the number of S. mansoni eggs per gram of tissue.282209214Barth, L.R., Fernandes, A.P., Rodrigues, V., Oviposition by Schistosoma mansoni during in vitro cultivation (1996) Rev Inst Med Trop São Paulo, 38, pp. 423-426Blanchard, T.J., Milne, L.M., Pollock, R., Coock, G.C., Early chemotherapy of imported neuroschistosomiasis (1993) Lancet, 341 (8850), p. 959Bonesso-Sabadini PIP. Avaliação da suscetibilidade da linhagem Ouh (Ourinhos, Vale do Paranapanema - SP) de Schistosoma mansoni ao oxamniquine e praziquantel [Dissertação] Campinas: Instituto de Biologia, UNICAMP, 1995Christopherson, J.B., The successful use of antimiony in bilhaziasis (1918) Lancet, 2, pp. 325-327Cinto, P.O., Avaliação da absorção intestinal de praziquantel veiculado em lipossomas (2005) Araraquara: Faculdade de Ciências Farmacêuticas, , Dissertação, UNESPCunha, A.S., Schistosomiasis mansoni - drug therapeutic (1992) Mem Inst Oswaldo Cruz, 87 (SUPPL. 4), pp. 341-351Delgado, V.S., Suárez, D.P., Cesari, I.M., Hincan, R.N., Experimental chemotherapy of Schistosoma mansoni with praziquantel and oxamniquine: Differential effect of single or combined formulations of drugs on various strins on both sexes of the parasite (1992) Prasitol Res, 78, pp. 648-654El-Ridi, R., Ozaki, T., Inaba, T., Ito, M., Kamiya, M., Schistosoma mansoni oviposition in vitro reflects worm fecundity in vivo: Individual, parasite age and host dependent variations (1997) Int J Parasitol, 27, pp. 381-387Frézard, F., Melo, A.L., Evaluation of the schistomicidal efficacy of lipossome-entrapped oxamniquine (1997) Rev Inst Med Trop São Paulo, 39 (2), pp. 91-100Frezza TF. Avaliação do efeito do praziquantel associado a lipossomas em Schistosoma mansoni in vivo [Dissertação] Campinas: Instituto de Biologia, UNICAMP, 2007Gönnert, R., Andrews, P., Praziquantel, a new broad-spectrum antischistosomal agent (1977) Z Parasitenkd, 52, pp. 129-150Hill, J., Rust, M.A., Pellegrino, J., Faria, J., Use of the oogram to reveal the effect of a nitrofurylacrylamide on the eggs of Schistosoma mansoni (1966) J Parasitol, 52, p. 822Kikuth, E., Gönnert, R., Experimental studies on the therapy of schistosomiasis (1948) Ann Trop Med Parasitol, 42, pp. 256-267Lambert, C.R., Chemotherapy of experimental Schistosoma mansoni infection with a nitro-thiazole derivate, CIBA 32,644-Ba (1964) Ann Trop Med Parasitol, 58, pp. 293-303Martinez, E.M., Neves, R.H., Oliveira, R.M.F., Machado-Silva, J.R., Rey, L., Características biológicas e morfológicas de cepas brasileiras de Schistosma mansoni em Mus musculus. (2003) Rev Soc Bras Med Trop, 36 (5), pp. 557-564Monteiro, W., Pellegrino, J., Silva, M.L.H., Unusual oogram pattern in mice after niridazole treatment (1968) J Parasitol, 54, pp. 175-176Mourão, S.C., Preparação e caracterizaçã o de lipossomas contendo praziquantel (2001) Araraquara: Faculdade de Ciências Farmacêuticas, , Dissertação, UNESP;Mourão, S.C., Costa, P.I., Salgado, H.R.N., Gremião, M.P.D., Improvement of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes (2005) Int J Pharm, 295, pp. 157-162Olivier, L., Stirewalt, M.A., An efficient meted for exposure of mice to cercarie of Schistosoma mansoni (1952) J Parasitol, 38, pp. 19-23Paraense, W.L., Corrêa, L.R., Variation in susceptibility of populations of Australorbis glabratus to strain of Schistosoma mansoni (1963) Rev Inst Med Trop São Paulo, 5, pp. 15-22Pellegrino, J., Oliveira, C.A., Faria, J., Cunha, A.S., New approach to the screening of drugs in experimental schistosomiasis mansoni in mice (1962) Am J Trop Med Hyg, 11, pp. 201-215Pellegrino, J., Katz, N., Experimental chemotherapy of schistosomiasis mansoni (1968) Adv Parasitol, 6, pp. 233-290Pimentel-Gomes, F., (2000) Curso de estatística experimental, , 14.ed. Piracicaba: USP/ESALQ;, 477pPrata, A., Tipos de ovos de Schistosoma mansoni (1957) Biópsia retal na esquistossomose mansoni: Bases e aplicações no diagnóstico e tratamento, pp. 15-60. , Rio de Janeiro: Serviço Nacional de Educação Sanitária;Richards, H.C., Foster, R., A new series of 2-aminomethytetra hydroquinaline derivates displaying schistosomicidal activity in rodents and primates (1969) Nature, 222, pp. 581-582Richards, F., Sullivan, J., Ruiz-Tiben, E., Eberhard, M., Bishop, H., Effect of praziquantel on the eggs of Schistosoma mansoni, with a note on the implications for managing central nervous system schistosomiasis (1989) Ann Trop Med Parasitol, 83 (5), pp. 465-472(1996) SAS user's guide, , SAS Institute Incorporation, statistics release 6.12. North Caroline: Cory;, 1098pStirewalt, M.A., Effect of snail maintenance temperatures on development of Schistosoma mansoni (1954) Exp Parasitol, 3, pp. 504-516Thomas, H., Gönnert, R., The efficacy of praziquantel against cestodes in animals (1977) Z Parasitenkd, 52, pp. 117-127Wahl, S.M., Frazier-Jessen, M., Jin, W.W., Kopp, J.B., Sher, A., Cheever, A.W., Cytokine regulation of schistosome-induced granuloma and fibrosi (1997) Kidney Int, 5, pp. 1370-137

Nanostructured Lipid Carriers As A Strategy To Improve The In Vitro Schistosomiasis Activity Of Praziquantel

Praziquantel (PZQ) is a pyrazinoisoquinoline anthelmintic that was discovered in 1972 by Bayer Germany. Currently, due to its efficacy, PZQ is the drug of choice against all species of Schistosoma. Although widely used, PZQ exhibits low and erratic bioavailability because of its poor water solubility. Nanostructured lipid carriers (NLC), second-generation solid lipid nanoparticles, were developed in the 1990s to improve the bioavailability of poorly water soluble drugs. The aim of this study was to investigate nanostructured lipid carriers as a strategy to improve the efficacy of PZQ in S. mansoni treatment. We prepared NLC2 and NLC4 by adding seventy percent glycerol monostearate (GMS) as the solid lipid, 30% oleic acid (OA) as the liquid lipid and two surfactant systems containing either soybean phosphatidylcholine/poloxamer (PC/P-407) or phosphatidylcholine/Tween 60 (PC/T60), respectively. The carriers were characterized by nuclear magnetic resonance, differential scanning calorimetry, thermogravimetric analysis and Fourier transform-infrared spectroscopy. The safety profile was evaluated using red cell hemolysis and in vitro cytotoxicity assays. The results showed that the encapsulation of PZQ in NLC2 or NLC4 improved the safety profile of the drug. Treatment efficacy was evaluated on the S. mansoni BH strain. PZQ-NLC2 and PZQ-NLC4 demonstrated an improved efficacy in comparison with free PZQ. The results showed that the intestinal transport of free PZQ and PZQ-NLC2 was similar. However, we observed that the concentration of PZQ absorbed was smaller when PZQ was loaded in NLC4. The difference between the amounts of absorbed PZQ could indicate that the presence of T60 in the nanoparticles (NLC4) increased the rigid lipid matrix, prolonging release of the drug. Both systems showed considerable in vitro activity against S. mansoni, suggesting that these systems may be a promising platform for the administration of PZQ for treating schistosomiasis.151761772Barsoum, R.S., Esmat, G., El-Baz, T., (2013) Journal of Advanced Research, 4, p. 433De Oliveira, R.N., Rehder, V.L.G., Santos Oliveira, A.S., Júnior, Í.M., De Carvalho, J.E., De Ruiz, A.L.T.G., De Lourdes Sierpe Jeraldo, V., Allegretti, S.M., (2012) Experimental Parasitology, 132, p. 135Allegretti, S.M., Oliveira, C.N.F., Oliveira, R.N., Frezza, T.F., Rehder, V.L.G., (2012), 27. , www.intechopen.com/books/schistosomiasisBygott, J.M., Chiodini, P.L., (2009) Acta Tropica, 111, p. 95Zhang, S.-M., Coultas, K.A., (2013) International Journal for Parasitology: Drugs and Drug Resistance, 3, p. 28Gryseels, B., Polman, K., Clerinx, J., Kestens, L., (2006) The Lancet, 368, p. 1106Doenhoff, M.J., Cioli, D., Utzinger, J., (2008) Curr. Opin. Infect. Dis., 1, p. 659Stelma, F.F., Talla, I., Sow, S., Kongs, A., Niang, M., Polman, K., Deelder, A.M., Gryseels, B., (1995) Am. J. Trop. Med. Hyg., 53, p. 167Mourao, S.C., Costa, P.I., Salgado, H.R., Gremiao, M.P., (2005) Int. J. Pharm., 295, p. 157Frezza, T.F., Madi, R.R., Banin, T.M., Pinto, M.C., Souza, A.L.R., Gremião, M.P.D., Allegretti, S.M., (2007) Journal of Basic and Applied Pharmaceutical Sciences, 28, p. 209Yang, L., Geng, Y., Li, H., Zhang, Y., You, J., Chang, Y., (2009) Pharmazie, 64, p. 86Souza, A., Andreani, T., Nunes, F., Cassimiro, D., Almeida, A., Ribeiro, C., Sarmento, V., Souto, E., (2012) J. Therm. Anal. Calorim., 108, p. 353Almeida, A., Souza, A., Cassimiro, D., Gremião, M., Ribeiro, C., Crespi, M., (2012) J. Therm. Anal. Calorim., 108, p. 333Souza, A.L.R., Kiill, C.P., Santos, F.K., Luz, G.M., Silva, H.R., Chorilli, M., Gremião, M.P.D., (2012) Current Nanoscience, 8, p. 512Santos, F.K., Oyafuso, M.H., Kiill, C.P., Gremiao, M.P.D., Chorilli, M., (2013) Current Nanoscience, 9, p. 159Cinto, P., Souza, A., Lima, A., Chaud, M., Gremião, M., (2009) Chromatographia, 69, p. 213Frezza, T.F., Gremião, M.P.D., Zanotti-magalhães, E.M., Magalhães, L.A., Souza, A.L.R., Allegretti, S.M., (2013) Acta TropicaCampos, F.D.S., Cassimiro, D.L., Crespi, M.S., Almeida, A.E., Gremião, M.P.D., (2013) Brazilian Journal of Pharmaceutical Sciences, 49, p. 75Müller, R.H., Petersen, R.D., Hommoss, A., Pardeike, J., (2007) Advanced Drug Delivery Reviews, 59, p. 522Han, F., Li, S., Yin, R., Liu, H., Xu, L., (2008) Colloids Surf., A: Physicochemical and Engineering Aspects, 315, p. 210Martins, S., Silva, A.C., Ferreira, D.C., Souto, E.B., (2009) Journal Biomedical Nanotechnology, 5, p. 76Silva, A.C., Santos, D., Ferreira, D.C., Souto, E.B., (2009) Pharmazie, 64, p. 177Jumaa, M., Kleinebudde, P., Müller, B.W., (1999) Pharmaceutica Acta Helvetiae, 73, p. 293Huang, Z.R., Hua, S.C., Yang, Y.L., Fang, J.Y., (2008) Acta Pharmacol. Sin., 29, p. 1094Olivier, L., Stirewalt, M.A., (1952) The Journal of Parasitology, 38, p. 19Smithers, S.R., Terry, R.J., (1965) Parasitology, 55, p. 695Xiao, S.H., Keiser, J., Chollet, J., Utzinger, J., Dong, Y., Endriss, Y., Vennerstrom, J.L., Tanner, M., (2007) Antimicrob. Agents Chemother., 51, p. 1440Cassimiro, D.L., Ferreira, L.M.B., Capela, J.M.V., Crespi, M.S., Ribeiro, C.A., (2013) Journal Of Pharmaceutical and Biomedical Analysis, 73, p. 24Garnero, C., Zoppi, A., Genovese, D., Longhi, M., (2010) Carbohydrate Research, 345, p. 2550Bottom, R., (2008) Thermogravimetric Analysis, Principles and Applications of Thermal Analysis, p. 87. , Blackwell Publishing LtdJores, K., Mehnert, W., Mader, K., (2003) Pharm. Res., 20, p. 1274Ali, H., El-Sayed, K., Sylvester, P.W., Nazzal, S., (2010) Colloids Surf. B Biointerfaces, 77, p. 286Pople, P.V., Singh, K.K., (2011) Eur. J. Pharm. Biopharm., 79, p. 82De Jesus, M.B., Pinto, L.M.A., Fraceto, L.F., Takahata, L.A.Y., Jaime, P.E.C., (2006) J. Pharm. Biomed. Anal., 41, p. 1428Hi, E.-S., Aa, A.-B., (1998) Analytical Profiles of Drug Substances and Excipients, 25, p. 463Schepmann, D., Blaschke, G., (2001) J. Pharm. Biomed. Anal., 26, p. 791Malheiros, S.V.P., Meirelles, N.C., De Paula, E., (2000) Biophys. Chem., 83, p. 89Raina, N., Goyal, A.K., Pillai, C.R., Rath, G., (2013) Indian Journal of Pharmaceutical Education and Research, 47, p. 123Abbasalipourkabir, R., Salehzadeh, A., Abdullah, R., (2011) Biotechnology, 10, p. 528Chiann, C., Gonçalves, J.E., Gai, M.N.M.N., Storpirtis, S.S., (2009) Biofarmacotécnica, 1, p. 352. , Guanabara Koogan, São PauloBaldrick, P., (2000) Regulatory Toxicology and Pharmacology, 32, p. 210Custodio, J.M., Wu, C.Y., Benet, L.Z., (2008) Advanced Drug Delivery Reviews, 60, p. 717Disch, J., Katz, N., Pereira E Silva, Y., De Gouvea Viana, L., Andrade, M.O., Rabello, A., (2002) Acta Trop, 81, p. 133Cioli, D., Pica-Mattoccia, L., (2003) Parasitol. Res., 90, p. 22Oliveira, C.N.F.D., Oliveira, R.N.D., Frezza, T.F., Rehder, V.L.C.G., Allegretti, S.M., (2013) Tegument of Schistosoma Mansoni as A Therapeutic Target, Parasitic Diseases-SchistosomiasisVan Hellemond, J.J., Retra, K., Brouwers, J.F., Van Balkom, B.W., Yazdanbakhsh, M., Shoemaker, C.B., Tielens, A.G., (2006) Int. J. Parasitol., 36, p. 691Barth, L.R., Fernandes, A.P., Rodrigues, V., (1996) Rev. Inst. Med. Trop. Sao Paulo, 38, p. 423Wilson, T.H., Wiseman, G., (1954) J. Physiol., 123, p. 116Balimane, P.V., Chong, S., Morrison, R.A., (2000) J. Pharmacol. Toxicol. Methods, 44, p. 30

Total Pancreatectomy: Porcine Model for Inducing Diabetes – Anatomical Assessment and Surgical Aspects

&lt;i&gt;Background:&lt;/i&gt; The swine is an essential model for carrying out preclinical research and for teaching complex surgical procedures. There is a lack of experimental models describing anatomical and surgical aspects of total pancreatectomy in the pig. &lt;i&gt;Materials and Methods:&lt;/i&gt; The experiments were performed on 10 white male swine weighing 27–33 kg. The animals were premedicated with midazolam (0.4 mg/kg, i.m.) and ketamine (4 mg/kg, i.m.). Anesthesia was induced with propofol (1–2 mg/kg, i.v.) and was maintained with propofol and fentanyl (0.3 mg and 0.1 µg/kg/min, respectively, i.v.). The surgical period ranged from 44 to 77 min. The pancreas anatomy, and the main arterial, venous and pancreatic duct anatomy were assessed. &lt;i&gt;Results:&lt;/i&gt; The pancreas anatomy was composed of 3 lobes, the ‘splenic’, ‘duodenal’ and ‘connecting’ lobe which is attached to the anterior portion of the portal vein. The splenic artery and the junction of the splenic vein and portal vein were divided. The left gastric artery was dissected and separated from its origin at the splenic artery. The head of the pancreas is disposed in a C shape. The pancreas was dissected and liberated from the right portion of the portal vein and the infrahepatic vena cava. The pancreas was separated from the duodenum preserving the pancreaticoduodenal artery, then we performed the total pancreatectomy preserving the duodenum, common bile duct and spleen. &lt;i&gt;Conclusion:&lt;/i&gt; Total pancreatectomy with duodenum, bile duct and spleen preservation in the pig is feasible and an important instrument for research purposes and teaching surgical technique.</jats:p

Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil

AbstractInvasive fungal disease (IFD) shows distinct regional incidence patterns and epidemiological features depending on the geographic region. We conducted a prospective survey in eight centres in Brazil from May 2007 to July 2009. All haematopoietic cell transplant (HCT) recipients and patients with acute myeloid leukaemia (AML) or myelodysplasia (MDS) were followed from admission until 1 year (HCT) or end of consolidation therapy (AML/MDS). The 12-month cumulative incidence (CI) of proven or probable IFD was calculated, and curves were compared using the Grey test. Among 237 AML/MDS patients and 700 HCT recipients (378 allogeneic, 322 autologous), the 1-year CI of IFD in AML/MDS, allogeneic HCT and autologous HCT was 18.7%, 11.3% and 1.9% (p <0.001), respectively. Fusariosis (23 episodes), aspergillosis (20 episodes) and candidiasis (11 episodes) were the most frequent IFD. The 1-year CI of aspergillosis and fusariosis in AML/MDS, allogeneic HCT and autologous HCT were 13.4%, 2.3% and 0% (p <0.001), and 5.2%, 3.8% and 0.6% (p 0.01), respectively. The 6-week probability of survival was 53%, and was lower in cases of fusariosis (41%). We observed a high burden of IFD and a high incidence and mortality for fusariosis in this first multicentre epidemiological study of IFD in haematological patients in Brazil

Diminishing benefits of urban living for children and adolescents’ growth and development

Optimal growth and development in childhood and adolescence is crucial for lifelong health and well-being1–6. Here we used data from 2,325 population-based studies, with measurements of height and weight from 71 million participants, to report the height and body-mass index (BMI) of children and adolescents aged 5–19 years on the basis of rural and urban place of residence in 200 countries and territories from 1990 to 2020. In 1990, children and adolescents residing in cities were taller than their rural counterparts in all but a few high-income countries. By 2020, the urban height advantage became smaller in most countries, and in many high-income western countries it reversed into a small urban-based disadvantage. The exception was for boys in most countries in sub-Saharan Africa and in some countries in Oceania, south Asia and the region of central Asia, Middle East and north Africa. In these countries, successive cohorts of boys from rural places either did not gain height or possibly became shorter, and hence fell further behind their urban peers. The difference between the age-standardized mean BMI of children in urban and rural areas was &amp;lt;1.1 kg m–2 in the vast majority of countries. Within this small range, BMI increased slightly more in cities than in rural areas, except in south Asia, sub-Saharan Africa and some countries in central and eastern Europe. Our results show that in much of the world, the growth and developmental advantages of living in cities have diminished in the twenty-first century, whereas in much of sub-Saharan Africa they have amplified. © 2023, The Author(s)